These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32903564)

  • 21. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
    Krivokuca A; Dobricic J; Brankovic-Magic M
    J BUON; 2013; 18(3):594-600. PubMed ID: 24065469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.
    Rechsteiner M; Dedes K; Fink D; Pestalozzi B; Sobottka B; Moch H; Wild P; Varga Z
    J Cancer Res Clin Oncol; 2018 May; 144(5):865-874. PubMed ID: 29453630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
    Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
    Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome.
    Ewald IP; Cossio SL; Palmero EI; Pinheiro M; Nascimento IL; Machado TM; Sandes KA; Toralles B; Garicochea B; Izetti P; Pereira ML; Bock H; Vargas FR; Moreira MÂ; Peixoto A; Teixeira MR; Ashton-Prolla P
    Genet Mol Biol; 2016; 39(2):223-31. PubMed ID: 27303907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mainstreaming genetic counseling for
    Verma A; Nag S; Hasan Q; Selvakumar VPP
    Indian J Cancer; 2019 Nov; 56(Supplement):S38-S47. PubMed ID: 31793441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
    BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
    Mitchell R; Buckingham L; Cobleigh M; Rotmensch J; Burgess K; Usha L
    PLoS One; 2018; 13(4):e0195497. PubMed ID: 29659587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening of
    Montalban G; Bonache S; Moles-Fernández A; Gisbert-Beamud A; Tenés A; Bach V; Carrasco E; López-Fernández A; Stjepanovic N; Balmaña J; Diez O; Gutiérrez-Enríquez S
    J Med Genet; 2019 Feb; 56(2):63-74. PubMed ID: 30472649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue.
    Adank MA; Brogi E; Bogomolniy F; Wadsworth EA; Lafaro KJ; Yee CJ; Kirchhoff T; Meijers-Heijboer EJ; Kauff ND; Boyd J; Offit K
    Fam Cancer; 2006; 5(4):337-42. PubMed ID: 16724247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of a BRCA2 Pathogenic Variant in Hereditary-Breast-and-Ovarian-Cancer-Syndrome Families with Increased Risk of Pancreatic Cancer in a Restricted Italian Area.
    Zampiga V; Cangini I; Bandini E; Azzali I; Ravegnani M; Ravaioli A; Mancini S; Tebaldi M; Tedaldi G; Pirini F; Veneroni L; Frassineti GL; Falcini F; Danesi R; Calistri D; Arcangeli V
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA-analyzer: Automatic workflow for processing NGS reads of BRCA1 and BRCA2 genes.
    Kechin A; Khrapov E; Boyarskikh U; Kel A; Filipenko M
    Comput Biol Chem; 2018 Dec; 77():297-306. PubMed ID: 30408727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing.
    Kang HP; Maguire JR; Chu CS; Haque IS; Lai H; Mar-Heyming R; Ready K; Vysotskaia VS; Evans EA
    PeerJ; 2016; 4():e2162. PubMed ID: 27375968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
    Fumagalli C; Tomao F; Betella I; Rappa A; Calvello M; Bonanni B; Bernard L; Peccatori F; Colombo N; Viale G; Barberis M; Guerini-Rocco E
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653094
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.